10-K: SWK Holdings Reports 2025 Net Loss Amid Strategic Shift

SWK Holdings Corporation reported a net loss of $2.5 million for the fiscal year ended December 31, 2025, driven by a strategic divestiture of its Pharmaceutical Development segment and increased tax expense.

Summary

• SWK Holdings Corporation reported a net loss of $2.5 million for the year ended December 31, 2025, a significant decrease from the net income of $13.5 million reported in 2024.
• Total revenues decreased to $41.5 million in 2025 from $45.0 million in 2024, primarily due to a $2.1 million decrease in Finance Receivables segment revenue and a $1.4 million decrease in Pharmaceutical Development segment revenue.
• The company completed the sale of substantially all assets of its Pharmaceutical Development segment (MOD3) during the third quarter of 2025, with future operations solely attributable to the Finance Receivables segment.
• Cash and cash equivalents increased significantly to $42.8 million as of December 31, 2025, from $5.9 million as of December 31, 2024, driven by interest, fees, principal, and royalty payments received, and proceeds from asset sales.
• A special cash dividend of $4.00 per share, totaling $49.1 million, was paid to shareholders in 2025 following the sale of a majority of the royalty portfolio to Soleus Capital for approximately $34.0 million.
• Income tax expense increased to $22.6 million in 2025 from $4.9 million in 2024, largely due to a $17.9 million valuation allowance recorded against deferred tax assets in connection with the anticipated merger.
• General and administrative expenses rose to $14.8 million in 2025 from $11.5 million in 2024, mainly due to increased compensation and legal costs.
• The company repurchased 199,218 shares of common stock at a cost of $3.1 million in 2025 under a program that was paused in August 2025.
• The aggregate commitments under the revolving credit facility were reduced from $60.0 million to $10.0 million in December 2025, and further to $7.5 million in February 2026, with no outstanding amount as of December 31, 2025.
• Merger Litigations were filed in March 2026, alleging that the proxy statement related to the merger with Runway Growth Finance Corp. is materially incomplete and misleading.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging period marked by a net loss and increased expenses, partially offset by a strong cash position and strategic divestiture. The pending merger and associated litigation introduce significant uncertainty.

Positives

• Cash and cash equivalents significantly increased to $42.8 million as of December 31, 2025, from $5.9 million in the prior year, indicating strong liquidity.
• The company successfully divested its Pharmaceutical Development segment, streamlining operations to focus on its core Finance Receivables business.
• A special cash dividend of $4.00 per share, totaling $49.1 million, was distributed to shareholders in 2025, returning capital to investors.
• The Finance Receivables segment is expected to generate positive cash flows in 2026, providing a stable outlook for the core business.
• The company is well-positioned to benefit from potential future increases in market interest rates due to the floating interest rates on the majority of its finance receivables.

Negatives

• The company reported a net loss of $2.5 million for the year ended December 31, 2025, a substantial decline from the $13.5 million net income in 2024.
• Total revenues decreased by $3.5 million in 2025 compared to 2024, with both operating segments experiencing revenue declines.
• Income tax expense surged to $22.6 million in 2025, primarily due to a $17.9 million valuation allowance against deferred tax assets, impacting profitability.
• General and administrative expenses increased by $3.3 million to $14.8 million in 2025, driven by higher compensation and legal costs.
• A $3.7 million loss on revaluation of finance receivables was recognized in 2025 due to the sale of a majority of the royalty portfolio.
• The company faces Merger Litigations filed in March 2026, alleging misleading proxy statements, which could lead to substantial costs and potential delays or prevention of the merger.
• The revolving credit facility commitments were significantly reduced from $60.0 million to $10.0 million in December 2025, and further to $7.5 million in February 2026, potentially limiting future borrowing capacity.

Risks

• The company may suffer losses on its principal invested in credit and royalty transactions, particularly from highly speculative small and middle-market life sciences businesses.
• Operating in a highly competitive market for investment opportunities, with many competitors having greater financial and managerial resources, could adversely affect business.
• The healthcare and life sciences industries are subject to extensive government regulation, litigation risk, and reimbursement risk, which could impair the ability to collect payments or decrease royalty income.
• The pharmaceutical industry faces numerous risks, including competition, extensive government regulation, product liability, patent exclusivity, and commercial difficulties.
• The business, financial condition, results of operations, liquidity, and cash flows depend on the accuracy of management's assumptions and estimates, and significant gains or losses could occur if these differ from actual results.
• The company generally does not control its partner companies, which may make decisions that do not serve its business or financial interests.
• Adverse developments affecting the financial services industry, including liquidity concerns or defaults by financial institutions, could adversely affect the company's business or portfolio companies.
• Quarterly and annual operating results are subject to fluctuation due to various factors, potentially leading to a decline in common stock price if investment objectives are not met.
• Investments in royalty-related transactions depend on third parties to market royalty-generating products, and poor marketing efforts or abandonment of products could adversely affect assets.
• The Finance Receivables segment has a limited number of assets, increasing the risk of significant loss if any debt securities decline in value or royalty investments underperform.
• The allowance for credit losses may prove inadequate if credit quality of partner companies declines or market conditions deteriorate.
• A rise in reference rates could adversely impact the ability of partner companies to service their debt obligations to the company.
• Fluctuations in the price of publicly traded equity holdings and the price at which they are sold may affect the price of the company's common stock.
• The company's financial condition and results of operations depend on its ability to manage future growth of the Finance Receivables segment effectively.
• The ability to use Net Operating Loss (NOL) carryforwards to offset future taxable income may be limited by Section 382 of the Internal Revenue Code, potentially increasing future cash tax liability.
• Changes in tax law may adversely affect the company or its investors.
• Engaging in acquisitions, divestitures, and joint ventures may lead to difficulties in integration or separation, and anticipated benefits may not be realized.
• The company is dependent upon its key management personnel for future success, and the loss of their services could have a material adverse effect.
• Changes in management may cause uncertainty in, or be disruptive to, the business.
• As a controlled company under Nasdaq listing standards, the company may not comply with certain corporate governance requirements, potentially reducing protections for stockholders.
• Inability to obtain additional debt or equity financing on commercially reasonable terms could materially adversely affect the business.
• The company may not be able to generate sufficient cash to service all of its debt and may be forced to take other actions that may not be successful.
• The use of leverage may limit operational flexibility and increase overall risk, adversely affecting business and results of operations.
• The liquidity, market price, and volume of the company's stock are volatile.
• Funds affiliated with Carlson Capital, L.P. control 75.1% of the common stock, allowing them to control or exert significant influence over management and policies.
• Substantial sales of shares of common stock, particularly by significant stockholders like Carlson, could cause the price of common stock to decline.
• Provisions in the certificate of incorporation and bylaws, and the Rights Agreement, could delay or prevent an acquisition of the company.
• If deemed an investment company under the Investment Company Act of 1940, applicable restrictions could make it impractical to continue business as contemplated.
• Failure to deal appropriately with conflicts of interest could damage the company's reputation and adversely affect its businesses.
• Cybersecurity incidents and other disruptions to information technology systems, or those of third parties, may compromise information and expose the company to liability.
• Public health epidemics, pandemics, or outbreaks could adversely affect the company's and its partner companies' businesses.
• Economic recessions or downturns could impair the ability of partner companies to repay loans, increasing non-performing assets and decreasing asset value.
• Some partner companies may be unable to protect their proprietary rights or may infringe on the proprietary rights of others.
• The development of products by life science companies requires significant research and development, clinical trials, and regulatory approvals, with no assurance of market acceptance.
• Changes in healthcare laws and other regulations applicable to partner companies' businesses may constrain their ability to offer products and services.
• The potential inability of partner companies and counterparties to charge desired prices for prescription drugs could impact their revenues and ability to repay the company.
• Stockholders will experience a reduction in percentage ownership and voting power in the combined company as a result of the Mergers.
• The announcement and pendency of the Mergers could adversely affect the company's businesses, financial results, and operations.
• If the Mergers do not close, the company will not benefit from the expenses incurred in pursuit of the Mergers.
• The termination of the Merger Agreement could negatively impact the company's business.
• The Merger Agreement limits the company's ability to pursue alternatives to the Mergers.
• The Mergers are subject to closing conditions, including approval by company stockholders, that, if not satisfied or waived, will result in the Mergers not being completed.
• The company will be subject to operational uncertainties and contractual restrictions while the Mergers are pending.
• Litigation filed against RWAY or the company in connection with the Mergers could result in substantial costs and could delay or prevent the Mergers from being completed.
• The Mergers may trigger certain change of control provisions and other restrictions in contracts, and the failure to obtain required consents or waivers could adversely impact the combined company.
• The shares of RWAY common stock to be received by stockholders as a result of the Mergers will have different rights associated with them than the company's common stock.
• Stockholders may receive a form or combination of consideration different from what they elect in the Mergers.
• The market price of RWAY common stock will continue to fluctuate after the Mergers, potentially leading to a loss of investment value for former stockholders.
• The fair value of investments may not align with the figures reported in the pro forma filings by RWAY or in the company's Proxy Statement.

Future Outlook

The company expects its Finance Receivables segment to be the sole operating segment in subsequent years following the divestiture of the Pharmaceutical Development segment. It anticipates positive cash flows from its finance receivables portfolio in 2026 and believes it is well-positioned to benefit from rising market interest rates due to the floating interest rates on most of its debt instruments. The merger with Runway Growth Finance Corp. is expected to close in the first half of 2026, subject to customary closing conditions.

Management Comments

• We believe we face less competition in transactions that are less than $50.0 million.
• We believe we are well positioned to benefit should market interest rates rise in the future.
• The Company denies all allegations in the Merger Litigations and the Demand Letters, believes that no additional disclosure is required in the proxy statement, and intends to vigorously defend against these and any similar Merger Litigations and Demand Letters.

Industry Context

StockSavvy.ai notes that SWK Holdings' strategic shift to solely focus on its Finance Receivables segment aligns with a broader trend in the life sciences sector towards specialized financing solutions. The divestiture of the Pharmaceutical Development segment, particularly a CDMO business, could reflect a move away from capital-intensive, highly regulated manufacturing towards a more asset-light, royalty-based model, which is common among certain investment funds in the healthcare space. The competitive landscape for sub-$50 million transactions, where SWK aims to operate, suggests a niche strategy to avoid direct competition with larger, more diversified financial institutions.

Comparison to Industry Standards

• SWK Holdings' focus on sub-$50 million life science financing transactions positions it in a niche market, contrasting with larger competitors like Royalty Pharma plc, which typically targets larger royalty streams and has greater financial resources.
• The divestiture of the Pharmaceutical Development segment, including CDMO services, indicates a strategic streamlining, moving away from direct operational involvement in drug development and manufacturing, unlike integrated pharmaceutical companies such as Pfizer or Johnson & Johnson.
• The company's reliance on floating interest rates for its finance receivables positions it to potentially outperform peers with fixed-rate portfolios in a rising interest rate environment, similar to how some specialized debt funds structure their portfolios.

Management Changes

Corporate Governance

Legal Proceedings

• On March 6, 2026, a purported individual shareholder, Eric Brady, filed a complaint in New York state court (No. 651394/2026) against the company and certain board members in connection with the Mergers.
• On March 9, 2026, another purported individual shareholder, Anthony Malone, filed a similar complaint in the same court (No. 651422/2026) against the same defendants.
• These Merger Litigations generally allege that the proxy statement issued on Schedule 14A on March 3, 2026, is materially incomplete and misleading, asserting claims for negligent misrepresentation, concealment, and negligence under New York common law.
• The Merger Litigations seek, among other things, an injunction enjoining consummation of the Mergers, rescission of the Mergers, and recovery of costs including attorneys' and experts' fees.
• The company has also received multiple demand letters from purported stockholders alleging similar omissions and demanding additional disclosures.
• The company denies all allegations in the Merger Litigations and Demand Letters, believes no additional disclosure is required, and intends to vigorously defend against these actions.

Related Party Transactions

• Carlson Capital, L.P. (Carlson) and its affiliates owned 75.1% of the company's combined issued and outstanding common stock and unvested restricted stock as of December 31, 2025.
• A Stockholders Agreement, amended on February 27, 2023, grants Carlson the right to approve specific transactions, including incurrence of indebtedness over specified amounts, sale of assets over specified amounts, declaration of dividends, loans, capital contributions to or investments in any third party over specified amounts, changes in the size of the board of directors, and repurchases of common stock.
• A Registration Rights Agreement, dated September 6, 2013, led to the filing of a Registration Statement on Form S-3 to register all common stock owned by Carlson for sale in the public market.

Stakeholder Impact

• Shareholders may experience a reduction in their percentage ownership and voting power in the combined company post-merger.
• Shareholders will receive consideration in the merger, which may be different from their election (cash or stock).
• Shareholders received a significant special cash dividend of $4.00 per share in 2025.
• The market price of the company's common stock could decline due to potential substantial sales by Carlson Capital, L.P.
• Shareholders are exposed to risks from ongoing merger litigation, which could delay or prevent the merger and incur substantial costs.
• Employees may face uncertainty or disruption due to the pending merger and management changes.
• Customers and business partners in the Finance Receivables segment will continue to be offered customized financing solutions in the life sciences sector.
• Creditors' ability to receive timely payments on debt obligations depends on the company's financial performance and cash flow generation.
• The reduction in the revolving credit facility commitments could impact the company's future financing flexibility.

Next Steps

• The closing of the merger with Runway Growth Finance Corp. is expected to occur in the first half of 2026, subject to customary closing conditions and stockholder approval.
• The company intends to vigorously defend against the Merger Litigations and Demand Letters filed in March 2026.
• The company will continue to focus solely on its Finance Receivables segment as its primary operating business.
• A Proxy Statement for the 2026 Annual Meeting of Shareholders is to be filed no later than 120 days after December 31, 2025.
• Management will continue to assess the need for a valuation allowance on deferred tax assets at each reporting date.

Key Dates

Recommendation

The company is undergoing a significant strategic transformation with the divestiture of its Pharmaceutical Development segment and a pending merger with Runway Growth Finance Corp. While the increase in cash and special dividend are positive, the net loss, increased tax expense due to valuation allowance, and ongoing merger litigation introduce considerable uncertainty. Investors should hold to observe the successful completion of the merger and the performance of the streamlined Finance Receivables segment before making further investment decisions.

Keywords

specialty finance, life sciences, royalty financing, debt financing, SEC filing, 10-K, financial results, corporate governance, risk management, merger, Runway Growth Finance, SWK Holdings, dividends, cash flow, net operating loss, cybersecurity, divestiture, pharmaceutical development